Analysis Of Income And Expense [Abstract]

HEMOGENYX PHARMACEUTICALS PLC - Filing #5969073

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	- GBP	—	—	—	—	—	—	—	—	- GBP	—	—	—	—	—
Expenses by nature [abstract]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation expense	—	639,285 GBP	—	—	—	—	—	—	—	—	645,681 GBP	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- GBP	5,983,937 GBP	- GBP	- GBP	358,459 GBP	- GBP	- GBP	- GBP	- GBP	- GBP	5,793,426 GBP	- GBP	- GBP	903,067 GBP	- GBP	- GBP
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	5,977,640 GBP	—	—	—	—	—	—	—	—	5,787,611 GBP	—	—	—	—	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	6,297 GBP	—	—	—	—	—	—	—	—	5,815 GBP	—	—	—	—	—